Compare CNS & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNS | NUVB |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.9B |
| IPO Year | 2004 | N/A |
| Metric | CNS | NUVB |
|---|---|---|
| Price | $62.53 | $8.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $72.50 | $10.63 |
| AVG Volume (30 Days) | 539.9K | ★ 9.9M |
| Earning Date | 01-21-2026 | 11-03-2025 |
| Dividend Yield | ★ 3.95% | N/A |
| EPS Growth | ★ 18.87 | N/A |
| EPS | ★ 3.19 | N/A |
| Revenue | ★ $552,096,000.00 | $26,748,000.00 |
| Revenue This Year | $8.26 | $609.55 |
| Revenue Next Year | $10.55 | $197.91 |
| P/E Ratio | $19.71 | ★ N/A |
| Revenue Growth | 11.13 | ★ 1137.19 |
| 52 Week Low | $58.39 | $1.54 |
| 52 Week High | $100.19 | $8.95 |
| Indicator | CNS | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 46.82 | 67.31 |
| Support Level | $61.95 | $8.13 |
| Resistance Level | $63.59 | $8.95 |
| Average True Range (ATR) | 1.60 | 0.50 |
| MACD | 0.35 | -0.06 |
| Stochastic Oscillator | 68.77 | 70.46 |
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for around two thirds of its $90.9 billion in managed assets at the end of September 2025. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (26%) of its managed assets (base management fees) from institutional clients, 48% (54%) from open-end funds, and 13% (20%) from closed-end funds.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.